A PYMNTS Company

US: Yet another multibillion-dollar pharma merger announced

By  |  June 9, 2014

As the world’s pharmaceutical industry continues to see an influx of consolidation, reports say the latest merger was announced when Merck and Idenix Pharmaceuticals revealed plans to combine in a $3.85 billion deal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to a press release, the transaction has already been approved by the boards of directors for both firms. Merck plans to boost its hepatitis C treatment portfolio through acquiring Idenix, the company said.

    The transaction agreed upon includes the launch of a tender offer to acquire Idenix through one of Merck’s subsidiaries. The deal remains subject to regulatory approval as well.

    Full content: Market Watch

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.